Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00588198 · ClinicalTrials.gov registry record
Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma
A clinical trial of Melanoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 754
- Enrollment target
- 1
- Study location
NCT00588198 is a study of Melanoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 754 participants, roughly in line with the 704-participant average among 266 other Melanoma trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT00588198, a study of Melanoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 754 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if tumor cells can be detected in the peripheral blood and/or bone marrow of patients with melanoma.
Conditions Studied
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 754 participants |
| Start Date | 1991-10 |
| Est. Completion | 2009-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00588198
The ClinicalTrials.gov registry entry for NCT00588198 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 754 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 704-participant average among 266 other Melanoma trials with a reported enrollment target. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 0 interventions.
NCT00588198 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00588198 about?
NCT00588198 is a clinical study titled "Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma". The purpose of this study is to determine if tumor cells can be detected in the peripheral blood and/or bone marrow of patients with melanoma.
What is the current status of trial NCT00588198?
This trial is currently completed. The enrollment target is 754 participants. The study started on 1991-10. Estimated completion is 2009-09.
What conditions does trial NCT00588198 study?
This clinical trial studies the following conditions: Melanoma.
Who is sponsoring clinical trial NCT00588198?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00588198 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.